Idiopathic pulmonary fibrosis: An update

Annals of Medicine

Volumn 47, Issue 1, 2015, Pages 15-27

  Spagnolo, Paolo ^a   Sverzellati, Nicola ^b   Rossi, Giulio ^c   Cavazza, Alberto ^d   Tzouvelekis, Argyris ^e   Crestani, Bruno ^f,g   Vancheri, Carlo ^h  

^a UNIVERSITY OF BASEL   (Switzerland)

^b UNIVERSITY OF PARMA   (Italy)

^c UNIVERSITY OF MODENA AND REGGIO EMILIA   (Italy)

^d S MARIA NUOVA HOSPITAL   (Italy)

^e YALE UNIVERSITY SCHOOL OF MEDICINE   (United States)

^f BICHAT HOSPITAL   (France)

^g Service de Pneumologie A Département hospitalo universitaire FIRE   (France)

^h UNIVERSITY OF CATANIA   (Italy)

Author keywords

Diagnosis; Idiopathic pulmonary fibrosis; Nintedanib; Pirfenidone; Treatment; Usual interstitial pneumonia

Indexed keywords

ACETYLCYSTEINE; NINTEDANIB; PIRFENIDONE; ENZYME INHIBITOR; INDOLE DERIVATIVE; NONSTEROID ANTIINFLAMMATORY AGENT; PYRIDONE DERIVATIVE;

CLINICAL FEATURE; COMORBIDITY; COMPUTER ASSISTED TOMOGRAPHY; CORONARY ARTERY DISEASE; COUGHING; CRYOBIOPSY; CRYOTHERAPY; DIAGNOSTIC PROCEDURE; DISEASE COURSE; EMPHYSEMA; ENVIRONMENTAL EXPOSURE; EXTRACELLULAR MATRIX; FIBROSING ALVEOLITIS; FORCED VITAL CAPACITY; HEREDITY; HUMAN; LUNG ALVEOLUS EPITHELIUM CELL; LUNG FUNCTION TEST; LUNG LAVAGE; LUNG TRANSPLANTATION; MORTALITY; PALLIATIVE THERAPY; PRIORITY JOURNAL; PULMONARY HYPERTENSION; PULMONARY REHABILITATION; REVIEW; RISK FACTOR; SMOKING; SURVIVAL TIME; THORAX RADIOGRAPHY; THROMBOEMBOLISM; TOTAL LUNG CAPACITY; TRANSBRONCHIAL BIOPSY; AGED; HEALTH SERVICE; IDIOPATHIC PULMONARY FIBROSIS; MIDDLE AGED; PATHOLOGY;

AGED; ANTI-INFLAMMATORY AGENTS, NON-STEROIDAL; ENZYME INHIBITORS; HEALTH SERVICES NEEDS AND DEMAND; HUMANS; IDIOPATHIC PULMONARY FIBROSIS; INDOLES; MIDDLE AGED; PYRIDONES; RISK FACTORS;

EID: 84923310446     PISSN: 07853890     EISSN: 13652060     Source Type: Journal    
DOI: 10.3109/07853890.2014.982165     Document Type: Review

References (165)

1. Travis WD, Costabel U, Hansell DM, King TE, Lynch DA, Nicholson AG, et al. An official American Th oracic Society/European Respiratory Society statement: update of the international multidisciplinary Classification of the idiopathic interstitial pneumonias. Am J Respir Crit Care Med. 2013; 188: 733-48
2. Raghu G, Collard HR, Egan JJ, Martinez FJ, Behr J, Brown KK, et al. Idiopathic pulmonary fi brosis: evidence based guidelines for diagnosis and management. Am J Respir Crit Care Med. 2011; 183: 788-824
3. Iwai K, Mori T, Yamada N, Yamaguchi M, Hosoda Y. Idiopathic pulmonary fi brosis: epidemiologic approaches to occupational exposure. Am J Respir Crit Care Med. 1994; 150: 670-5
4. Bjoraker JA, Ryu JH, Edwin MK, Myers JL, Tazelaar HD, Schroeder DR, et al. Prognostic signifi cance of histopathologic subsets in idiopathic pulmonary fi brosis. Am J Respir Crit Care Med. 1998;157:199-203
5. Flaherty KR, Toews GB, Travis WD, Colby TV, Kazerooni EA, Gross BH, et al. Clinical signifi cance of histological Classification of idiopathic interstitial pneumonia. Eur Respir J. 2002; 19: 275-83
6. Nicholson AG, Colby TV, du Bois RM, Hansell DM, Wells AU. The prognostic signifi cance of the histologic pattern of interstitial pneumonia in patients presenting with the clinical entity of cryptogenic fi brosing alveolitis. Am J Respir Crit Care Med. 2000;162:2213-17
7. King TE Jr, Schwarz MI, Brown K, Tooze JA, Colby TV, Waldron JA Jr, et al. Idiopathic pulmonary fi brosis: relationship between histopathologic features and mortality. Am J Respir Crit Care Med. 2001;164:1025-32
8. Ley B, Collard HR, King TE Jr. Clinical course and prediction of survival in idiopathic pulmonary fi brosis. Am J Respir Crit Care Med. 2011; 183: 431-40
9. Olson AL, Swigris JJ. Idiopathic pulmonary fi brosis: diagnosis and epidemiology. Clin Chest Med. 2012; 33: 41-50
10. Coultas DB, Zumwalt RE, Black WC, Sobonya RE. The epidemiology of interstitial lung diseases. Am J Respir Crit Care Med. 1994;150:967-72
11. Raghu G, Weycker D, Edelsberg J, Bradford WZ, Oster G. Incidence and prevalence of idiopathic pulmonary fi brosis. Am J Respir Crit Care Med. 2006; 174: 810-16
12. Raghu G, Chen S-Y, Yeh W-S, Maroni B, Li Q, Lee Y-C, et al. Idiopathic pulmonary fi brosis in US Medicare benefi ciaries aged 65 years and older: incidence, prevalence and survival, 2001-11. Lancet Respir Med. 2014;2:566-72
13. Mannino DM, Etzel RA, Parrish RG. Pulmonary fi brosis deaths in the United States, 1979-1971. An analysis of multiple-cause mortality data. Am J Respir Crit Care Med. 1996; 153: 1548-52
14. O lson A L, Swigris J J, Lezotte D C, Norris J M, Wilson C G, Brown KK. Mortality from pulmonary fi brosis increased in the United States from 1992 to 2003. Am J Respir Crit Care Med. 2007; 176: 277-84
15. Navaratnam V, Fleming KM, West J, Smith CJ, Jenkins RG, Fogarty A, et al. The rising incidence of idiopathic pulmonary fi brosis in the U.K. Thorax. 2011;66:462-7
16. A merican Cancer Society. Cancer facts and fi gures 2 009. A tlanta: American Cancer Society; 2010
17. du Bois RM. An earlier and more confi dent diagnosis of idiopathic pulmonary fi brosis. Eur Respir Rev. 2012; 21: 141-6
18. Taskar VS, Coultas DB. Is idiopathic pulmonary fi brosis an environmental disease?. Proc Am Th orac Soc. 2006;3:293-8
19. Baumgartner KB, Samet JM, Stidley CA, Colby TV, Waldron JA. Cigarette smoking: a risk factor for idiopathic pulmonary fi brosis. Am J Respir Crit Care Med. 1997; 155: 242-8
20. Hubbard R, Lewis S, Richards K, Johnston I, Britton J. Occupational exposure to metal or wood dust and aetiology of cryptogenic fi brosing alveolitis. Lancet. 1996;347:284-9
21. Miyake Y, Sasaki S, Yokoyama T, Chida K, Azuma A, Suda T, et al. Occupational and environmental factors and idiopathic pulmonary fi brosis in Japan. Ann Occup Hyg. 2005; 49: 259-65
22. Baumgartner KB, Samet JM, Coultas DB, Stidley CA, Hunt WC, Colby TV, et al. Occupational and environmental risk factors for idiopathic pulmonary fi brosis: a multicenter case-control study. Am J Epidemiol. 2000; 152: 307-15
23. Folcik VA, Garofalo M, Coleman J, Donegan JJ, Rabbani E, Suster S, et al. Idiopathic pulmonary fi brosis is strongly associated with productive infection by herpesvirus saimiri. Mod Pathol. 2014;27:851-62
24. Molyneaux PL, Maher TM. The role of infection in the pathogenesis of idiopathic pulmonary fi brosis. Eur Respir Rev. 2013; 22: 376-81
25. Han MK, Zhou Y, Murray S, Tayob N, Noth I, Lama VN, et al. Lung microbiome and disease progression in idiopathic pulmonary fi brosis: an analysis of the COMET study. Lancet Respir Med. 2014; 2: 548-56
26. Molyneaux PL, Cox MJ, Willis-Owen SA, Mallia P, Russell KE, Russell AM, et al. The role of bacteria in the pathogenesis and progression of idiopathic pulmonary fi brosis. Am J Respir Crit Care Med. 2014 Sep 3. [Epub ahead of print]
27. Shulgina L, Cahn AP, Chilvers ER, Parfrey H, Clark AB, Wilson EC, et al. Treating idiopathic pulmonary fi brosis with the addition of co-trimoxazole: a randomised controlled trial. Thorax. 2013;68:155-62
28. Lee JS, Collard HR, Raghu G, Sweet MP, Hays SR, Campos GM, et al. Does chronic microaspiration cause idiopathic pulmonary fi brosis?. Am J Med. 2010; 123: 304-11
29. Tobin RW, Pope CE II, Pellegrini CA, Emond MJ, Sillery J, Raghu G. Increased prevalence of gastroesophageal refl ux in patients with idiopathic pulmonary fi brosis. Am J Respir Crit Care Med. 1998;158:1804-8
30. Sweet MP, Patti MG, Leard LE, Golden JA, Hays SR, Hoopes C, et al. Gastroesophageal refl ux in patients with idiopathic pulmonary fi brosis referred for lung transplantation. J Th orac Cardiovasc Surg. 2007;133:1078-84
31. Moran TJ. Experimental aspiration pneumonia. IV. Inflammatory and reparative changes produced by intratracheal injections of autologous gastric juice and hydrochloric acid. AMA Arch Pathol. 1955; 60: 122-9
32. Lee H, Ryu JH, Wittmer MH, Hartman TE, Lymp JF, Tazelaar HD, et al. Familial idiopathic pulmonary fi brosis: clinical features and outcome. Chest. 2005; 127: 2034-41
33. Spagnolo P, Grunewald J, du Bois RM. Genetic determinants of pulmonary fi brosis: evolving concepts. Lancet Respir Med. 2014; 2: 416-28
34. Nogee LM, Dunbar AE 3rd, Wert SE, Askin F, Hamvas A, Whitsett JA. A mutation in the surfactant protein C gene associated with familial interstitial lung disease. N Engl J Med. 2001; 344: 573-9
35. Thomas AQ, Lane K, Phillips J 3rd, Prince M, Markin C, Speer M, et al. Heterozygosity for a surfactant protein C gene mutation associated with usual interstitial pneumonitis and cellular nonspecifi c interstitial pneumonitis in one kindred. Am J Respir Crit Care Med. 2002;165:1322-8
36. Wang Y, Kuan PJ, Xing C, Cronkhite JT, Torres F, Rosenblatt RL, et al. Genetic defects in surfactant protein A2 are associated with pulmonary fi brosis and lung cancer. Am J Hum Genet. 2009; 4: 52-9
37. Maitra M, Wang Y, Gerard RD, Mendelson CR, Garcia CK. Surfactant protein A2 mutations associated with pulmonary fi brosis lead to protein instability and endoplasmic reticulum stress. J Biol Chem. 2010;285:22103-13
38. Mulugeta S, Nguyen V, Russo SJ, Muniswamy M, Beers MF. A surfactant protein C precursor protein BRICHOS domain mutation causes endoplasmic reticulum stress, proteasome dysfunction, and caspase 3 activation. Am J Respir Cell Mol Biol. 2005; 32: 521-30
39. Korfei M, Ruppert C, Mahavadi P, Henneke I, Markart P, Koch M, et al. Epithelial endoplasmic reticulum stress and apoptosis in sporadic idiopathic pulmonary fi brosis. Am J Respir Crit Care Med. 2008;178:838-46
40. A rmanios M Y, Chen J J, Cogan J D, Alder J K, Ingersoll R G, Markin C, et al. Telomerase mutations in families with idiopathic pulmonary fi brosis. N Engl J Med. 2007; 356: 1317-26
41. Tsakiri KD, Cronkhite JT, Kuan PJ, Xing C, Raghu G, Weissler JC, et al. Adult-onset pulmonary fi brosis caused by mutations in telomerase. Proc Natl Acad Sci USA 2007;104:7552-7
42. C ronkhite J T, Xing C, Raghu G, Chin K M, Torres F, Rosenblatt R L, et al. Telomere shortening in familial and sporadic pulmonary fi brosis. Am J Respir Crit Care Med. 2008; 178: 729-37
43. Alder JK, Chen JJ, Lancaster L, Danoff S, Su SC, Cogan JD, et al. Short telomeres are a risk factor for idiopathic pulmonary fi brosis. Proc Natl Acad Sci USA 2008; 105: 13051-6
44. Stuart BD, Lee JS, Kozlitina J, Noth I, Devine MS, Glazer CS, et al. Effect of telomere length on survival in patients with idiopathic pulmonary fi brosis: an observational cohort study with independent validation. Lancet Respir Med. 2014; 2: 557-65
45. Roy MG, Livraghi-Butrico A, Fletcher AA, McElwee MM, Evans SE, Boerner RM, et al. Muc5b is required for airway defence. Nature. 2014;505:412-16
46. Seibold MA, Wise AL, Speer MC, Steele MP, Brown KK, Loyd JE, et al. A common MUC5B promoter polymorphism and pulmonary fi brosis. N Engl J Med. 2011; 364: 1503-12
47. Peljto AL, Zhang Y, Fingerlin TE, Ma SF, Garcia JG, Richards TJ, et al. Association between the MUC5B promoter polymorphism and survival in patients with idiopathic pulmonary fi brosis. JAMA. 2013;309:2232-9
48. Noth I, Zhang Y, Ma S-F, Flores C, Barber M, Huang Y, et al. Genetic variants associated with idiopathic pulmonary fi brosis susceptibility and mortality: a genome-wide association study. Lancet Respir Med. 2013;1:309-17
49. Fingerlin TE, Murphy E, Zhang W, Peljto AL, Brown KK, Steele MP, et al. Genome-wide association study identifi es multiple susceptibility loci for pulmonary fi brosis. Nat Genet. 2013; 45: 613-20
50. Selman M, Pardo A. Idiopathic pulmonary fi brosis: an epithelial/fi broblastic cross-talk disorder. Respir Res. 2002; 3: 3
51. Wolters PJ, Collard HR, Jones KD. Pathogenesis of idiopathic pulmonary fi brosis. Annu Rev Pathol. 2014; 9: 157-79
52. Hinz B, Phan SH, Th annickal V J, Prunotto M, Desmoulière A, Varga J, et al. Recent developments in myofi broblast biology: paradigms for connective tissue remodeling. Am J Pathol. 2012;180:1340-55
53. Phan SH. Genesis of the myofi broblast in lung injury and fi brosis. Proc Am Th orac Soc. 2012;9:148-52
54. Strieter RM, Gomperts BN, Keane MP. The role of CXC chemokines in pulmonary fi brosis. J Clin Invest. 2007; 117: 549-56
55. Maher TM, Evans IC, Bottoms SE, Mercer PF, Th orley A J, Nicholson AG, et al. Diminished prostaglandin E2 contributes to the apoptosis paradox in idiopathic pulmonary fi brosis. Am J Respir Crit Care Med. 2010; 182: 73-82
56. Selman M, Pardo A. Revealing the pathogenic and aging-related mechanisms of the enigmatic idiopathic pulmonary fi brosis. An integral model. Am J Respir Crit Care Med. 2014; 189: 1161-72
57. Sanders YY, Pardo A, Selman M, Nuovo GJ, Tollefsbol TO, Siegal GP, et al. Th y-1 promoter hypermethylation: a novel epigenetic pathogenic mechanism in pulmonary fi brosis. Am J Respir Cell Mol Biol. 2008;39:610-18
58. Pandit KV, Milosevic J, Kaminski N. MicroRNAs in idiopathic pulmonary fi brosis. Transl Res. 2011; 157: 191-9
59. Cushing L, Kuang PP, Qian J, Shao F, Wu J, Little F, et al. miR-29 is a major regulator of genes associated with pulmonary fi brosis. Am J Respir Cell Mol Biol. 2011; 45: 287-94
60. Liu G, Friggeri A, Yang Y, Milosevic J, Ding Q, Th annickal VJ, et al. miR-21 mediates fi brogenic activation of pulmonary fi broblasts and lung fi brosis. J Exp Med. 2010; 207: 1589-97
61. Das S, Kumar M, Negi V, Pattnaik B, Prakash YS, Agrawal A, et al. MicroRNA-326 regulates pro-fi brotic functions of transforming growth factor-beta in pulmonary fi brosis. Am J Respir Cell Mol Biol. 2014;50:882-92
62. King TE Jr, Tooze JA, Schwarz MI, Brown KR, Cherniack RM. Predicting survival in idiopathic pulmonary fi brosis: scoring system and survival model. Am J Respir Crit Care Med. 2001; 164: 1171-81
63. Turner-Warwick M, Burrows B, Johnson A. Cryptogenic fi brosing alveolitis: clinical features and their infl uence on survival. Thorax. 1980;35:171-80
64. Meltzer EB, Noble PW. Idiopathic pulmonary fi brosis. Orphanet J Rare Dis. 2008; 3: 8
65. Fischer A, West SG, Swigris JJ, Brown KK, du Bois RM. Connective tissue disease-associated interstitial lung disease: a call for clarification. Chest. 2010; 138: 251-6
66. ViJr, Noth I, Strek ME. Autoimmune-featured interstitial lung disease: a distinct entity. Chest. 2011; 140: 1292-9
67. Alhamad EH, Lynch JP 3rd, Martinez FJ. Pulmonary function tests in interstitial lung disease: what role do they have?. Clin Chest Med. 2001;22:715-50, ix.
68. Ley B, Ryerson CJ, Vittinghoff E, Ryu JH, Tomassetti S, Lee JS, et al. A multidimensional index and staging system for idiopathic pulmonary fi brosis. Ann Intern Med. 2012; 156: 684-91
69. Zompatori M, Sverzellati N, Poletti V, Bn à C, Ormitti F, Spaggiari E, et al. High-resolution CT in diagnosis of diff use infi ltrative lung disease. Semin Ultrasound CT MR. 2005; 26: 332-47
70. Souza CA, Muller NL, Lee KS, Johkoh T, Mitsuhiro H, Chong S. Idiopathic interstitial pneumonias: prevalence of mediastinal lymph node enlargement in 206 patients. AJR Am J Roentgenol. 2006;186:995-9
71. Hunninghake GW, Zimmerman MB, Schwartz DA, King TE Jr, Lynch J, Hegele R, et al. Utility of a lung biopsy for the diagnosis of idiopathic pulmonary fi brosis. Am J Respir Crit Care Med. 2001;164:193-6
72. Hansell DM, Bankier AA, MacMahon H, McLoud TC, Muller NL, Remy J. Fleischner Society: glossary of terms for thoracic imaging. Radiology. 2008; 246: 697-722
73. Watadani T, Sakai F, Johkoh T, Noma S, Akira M, Fujimoto K, et al. Interobserver variability in the CT assessment of honeycombing in the lungs. Radiology. 2013; 266: 936-44
74. Jeong YJ, Lee KS, Chung MP, Han J, Johkoh T, Ichikado K. Chronic hypersensitivity pneumonitis and pulmonary sarcoidosis: differentiation from usual interstitial pneumonia using high-resolution computed tomography. Semin Ultrasound CT MR. 2014; 35: 47-58
75. Song JW, Do KH, Kim MY, Jang SJ, Colby TV, Kim DS. Pathologic and radiologic diff erences between idiopathic and collagen vascular disease-related usual interstitial pneumonia. Chest. 2009; 136: 23-30
76. Silva CI, Muller NL, Hansell DM, Lee KS, Nicholson AG, Wells AU. Nonspecifi c interstitial pneumonia and idiopathic pulmonary fi brosis: changes in pattern and distribution of disease over time. Radiology. 2008;247:251-9
77. Lloyd CR, Walsh SL, Hansell DM. High-resolution CT of complications of idiopathic fi brotic lung disease. Br J Radiol. 2011;84:581-92
78. Katzenstein AL, Fiorelli RF. Nonspecifi c interstitial pneumonia/fi brosis. Histologic features and clinical signifi cance. Am J Surg Pathol. 1994;18:136-47
79. Smith M, Dalurzo M, Panse P, Parish J, Leslie K. Usual interstitial pneumonia-pattern fi brosis in surgical lung biopsies. Clinical, radiological and histopathological clues to aetiology. J Clin Pathol. 2013;66:896-903
80. Tabata K, Fukuoka J. Histopathologic features of usual interstitial pneumonia and related patterns: what is important for radiologists?. Semin Ultrasound. 2014; 35: 2-11
81. N icholson A G, Colby T V, Wells AU. H istopathological approach to patterns of interstitial pneumonia in patient with connective tissue disorders. Sarcoidosis Vasc Diff use Lung Dis. 2002; 19: 10-17
82. Churg A, Muller NL, Flint J, Wright JL. Chronic hypersensitivity pneumonitis. Am J Surg Pathol. 2006; 30: 201-8
83. Takemura T, Akashi T, Kamiya H, Ikushima S, Ando T, Oritsu M, et al. Pathological diff erentiation of chronic hypersensitivity pneumonitis from idiopathic pulmonary fi brosis/usual interstitial pneumonia. Histopathology. 2012; 61: 1026-35
84. Cavazza A, Rossi G, Carbonelli C, Spaggiari L, Paci M, Roggeri A. The role of histology in idiopathic pulmonary fi brosis: an update. Respir Med. 2010; 104: S11-22
85. Larsen BT, Colby TV. Update for pathologists on idiopathic interstitial pneumonias. Arch Pathol Lab Med. 2012; 136: 1234-41
86. Flaherty KR, Travis WD, Colby TV, Toews GB, Kazerooni EA, Gross BH, et al. Histopathologic variability in usual and nonspecifi c interstitial pneumonias. Am J Respir Crit Care Med. 2001;164:1722-7
87. Katzenstein AL. S moking-related interstitial fi brosis (SRIF), pathogenesis and treatment of usual interstitial pneumonia (UIP), and transbronchial biopsy in UIP. Mod Pathol. 2012;25:S68-78
88. Nicholson AG, Addis BJ, Bharucha H, Clelland CA, Corrin B, Gibbs AR, et al. Inter-observer variation between pathologists in diff use parenchymal lung disease. Thorax. 2004;59:500-5
89. Flaherty KR, Andrei AC, King TE, Raghu G, Colby TV, Wells A, et al. Idiopathic interstitial pneumonia. Do community and academic physicians agree on diagnosis?. Am J Respir Crit Care Med. 2007;175:1054-60
90. Lettieri CJ, Veerappan GR, Parker JM, Franks TJ, Hayden D, Travis WD, et al. Discordance between general and pulmonary pathologists in the diagnosis of interstitial lung disease. Respir Med. 2005;99:1425-30
91. Katzenstein A-LA, Zisman DA, Litzky LA, Nguyen BT, Kotloff RM. Usual interstitial pneumonia: histologic study of biopsy and explant specimens. Am J Surg Pathol. 2002; 26: 1567-77
92. Katzenstein ALA, Mukhopadhyay S, Myers JL. Diagnosis of usual interstitial pneumonia and distinction from other fi brosing interstitial lung diseases. Hum Pathol. 2008; 39: 1275-94
93. Leslie KO. My approach to interstitial lung disease using clinical, radiological and histopathological patterns. J Clin Pathol. 2009;62:387-401
94. Ohshimo S, Bonella F, Cui A, Beume M, Kohno N, Guzman J, et al. Signifi cance of bronchoalveolar lavage for the diagnosis of idiopathic pulmonary fi brosis. Am J Respir Crit Care Med. 2009; 179: 1043-7
95. A merican Th oracic Society; European Respiratory Society. American Th oracic Society/European Respiratory Society International Multidisciplinary Consensus Classification of the Idiopathic Interstitial Pneumonias. Am J Respir Crit Care Med. 2002; 165: 277-304
96. Meyer KC. The role of bronchoalveolar lavage in interstitial lung disease. Clin Chest Med. 2004; 25: 637-49
97. T omassetti S, Cavazza A, Colby T V, Ryu J H, Nanni O, Scarpi E, et al. Transbronchial biopsy is useful in predicting UIP pattern. Respir Res. 2012;13:96
98. Berbescu EA, Katzenstein ALA, Snow JL, Zisman DA. Transbronchial biopsy in usual interstitial pneumonia. Chest. 2006; 129: 1126-31
99. Shim HS, Park MS, Park IK. Histopathologic fi nding of transbronchial biopsy in usual interstitial pneumonia. Pathol Intern. 2010; 60: 373-7
100. Babiak A, Hetzel J, Krishna G, Fritz P, Moeller P, Balli T, et al. Transbronchial cryobiopsy: a new tool for lung biopsies. Respiration. 2009;78:203-8
101. Casoni GL, Tomassetti S, Cavazza A, Colby TV, Dubini A, Ryu JH, et al. Transbronchial lung cryobiopsy in the diagnosis of fi brotic interstitial lung diseases. PLoS One. 2014; 9: e86716
102. King TE Jr. Idiopathic pulmonary fi brosis. In: King TE Jr, Schwarz MI, editors. Interstitial lung disease. 5Thed. Hamilton, ON, Canada: BC Decker;2010. p. 895-944
103. S elman M, Carrillo G, Estrada A, Mejia M, Becerril C, Cisneros J, et al. Accelerated variant of idiopathic pulmonary fi brosis: clinical behaviour and gene expression pattern. PLoS One. 2007; 2: e482
104. Collard HR, Moore BB, Flaherty KR, Brown KK, Kaner RJ, King TE Jr, et al .; Idiopathic Pulmonary Fibrosis Clinical Research Network Investigators. Acute exacerbations of idiopathic pulmonary fi brosis. Am J Respir Crit Care Med. 2007; 176: 636-43
105. Song JW, Hong SB, Lim CM, Koh Y, Kim DS. Acute exacerbation of idiopathic pulmonary fi brosis: incidence, risk factors and outcome. Eur Respir J. 2011; 37: 356-63
106. Kim DS. Acute exacerbation of idiopathic pulmonary fi brosis. Clin Chest Med. 2012; 33: 59-68
107. Kim DS, Park JH, Park BK, Lee JS, Nicholson AG, Colby T. Acute exacerbation of idiopathic pulmonary fi brosis: frequency and clinical features. Eur Respir J. 2006; 27: 143-50
108. Hyzy R, Huang S, Myers J, Flaherty K, Martinez F. Acute exacerbation of idiopathic pulmonary fi brosis. Chest. 2007; 132: 1652-8
109. Fell CD. Idiopathic pulmonary fi brosis: phenotypes and comorbidities. Clin Chest Med. 2012; 33; 51-7
110. Hoeper MM, Bogaard HJ, Condliff e R, Frantz R, Khanna D, Kurzyna M, et al. Defi nitions and diagnosis of pulmonary hypertension. J Am Coll Cardiol. 2013; 62(25 Suppl): D42-50
111. Patel NM, Lederer DJ, Borczuk AC, Kawut SM. Pulmonary hypertension in idiopathic pulmonary fi brosis. Chest. 2007; 132: 998-1006
112. Lettieri CJ, Nathan SD, Barnett SD, Ahmad S, Shorr AF. Prevalence and outcomes of pulmonary arterial hypertension in advanced idiopathic pulmonary fi brosis. Chest. 2006; 129: 746-52
113. Judge EP, Fabre A, Adamali HI, Egan JJ. Acute exacerbations and pulmonary hypertension in advanced idiopathic pulmonary fi brosis. Eur Respir J. 2012; 40: 93-100
114. Arcasoy SM, Christie JD, Ferrari VA, Sutton MS, Zisman DA, Blumenthal NP, et al. Echocardiographic assessment of pulmonary hypertension in patients with advanced lung disease. Am J Respir Crit Care Med. 2003; 167: 735-40
115. Fisher MR, Forfi a PR, Chamera E, Housten-Harris T, Champion HC, Girgis RE, et al. Accuracy of Doppler echocardiography in the hemodynamic assessment of pulmonary hypertension. Am J Respir Crit Care Med. 2009; 179: 615-21
116. Corte TJ, Keir GJ, Dimopoulos K, Howard L, Corris PA, Parfi tt L, et al. Bosentan in pulmonary hypertension associated with fi brotic idiopathic interstitial pneumonia. Am J Respir Crit Care Med. 2014;190:208-17
117. Harris JM, Johnston ID, Rudd R, Taylor AJ, Cullinan P. Cryptogenic fi brosing alveolitis and lung cancer: the BTS study. Thorax. 2010;65:70-6
118. Ozawa Y, Suda T, Naito T, Enomoto N, Hashimoto D, Fujisawa T, et al. Cumulative incidence of and predictive factors for lung cancer in IPF. Respirology. 2009; 14: 723-8
119. Hubbard R, Venn A, Lewis S, Britton J. Lung cancer and cryptogenic fi brosing alveolitis. A population-based cohort study. Am J Respir Crit Care Med. 2000; 161: 5-8
120. Daniels CE, Jett JR. Does interstitial lung disease predispose to lung cancer?. Curr Opin Pulm Med. 2005;11:431-7
121. Cottin V, Nunes H, Brillet PY, Delaval P, Devouassoux G, Tillie-Leblond I, et al. Combined pulmonary fi brosis and emphysema: a distinct underrecognised entity. Eur Respir J. 2005; 26: 586-93
122. Akagi T, Matsumoto T, Harada T, Tanaka M, Kuraki T, Fujita M, et al. Coexistent emphysema delays the decrease of vital capacity in idiopathic pulmonary fi brosis. Respir Med. 2009; 103: 1209-15
123. Wells AU, Desai SR, Rubens MB, Goh NS, Cramer D, Nicholson AG, et al. Idiopathic pulmonary fi brosis: a composite physiologic index derived from disease extent observed by computed tomography. Am J Respir Crit Care Med. 2003; 167: 962-9
124. Mejía M, Carrillo G, Rojas-Serrano J, Estrada A, Suárez T, Alonso D, et al. Idiopathic pulmonary fi brosis and emphysema: decreased survival associated with severe pulmonary arterial hypertension. Chest. 2009;136:10-15
125. Kizer JR, Zisman DA, Blumenthal NP, Kotloff RM, Kimmel SE, Strieter RM, et al. Association between pulmonary fi brosis and coronary artery disease. Arch Intern Med. 2004;164:551-6
126. Hubbard RB, Smith C, Le Jeune I, Gribbin J, Fogarty AW. The association between idiopathic pulmonary fi brosis and vascular disease: a population- based study. Am J Respir Crit Care Med. 2008; 178: 1257-61
127. Sode BF, Dahl M, Nielsen SF, Nordestgaard BG. Venous thromboembolism and risk of idiopathic interstitial pneumonia: a nationwide study. Am J Respir Crit Care Med. 2010; 181: 1085-92
128. Schunemann HJ, Jaeschke R, Cook DJ, Bria WF, El-Solh AA, Ernst A, et al. An official ATS statement: grading the quality of evidence and strength of recommendations in ATS guidelines and recommendations. Am J Respir Crit Care Med. 2006; 174: 605-14
129. Idiopathic Pulmonary Fibrosis Clinical Research Network; Martinez FJ, De Andrade JA, Anstrom KJ, King TE Jr, Raghu G. Prednisone, azathioprine, and N-acetylcysteine for pulmonary fi brosis. N Engl J Med. 2012; 366: 1968-77
130. Noth I, Anstrom KJ, Calvert SB, De Andrade J, Flaherty KR, Glazer C, et al. A placebo-controlled randomized trial of warfarin in idiopathic pulmonary fi brosis. Am J Respir Crit Care Med. 2012;186:88-95
131. I diopathic Pulmonary Fibrosis Clinical Research Network; Martinez FJ, De Andrade JA, Anstrom KJ, King TE Jr, Raghu G. Randomized trial of acetylcysteine in idiopathic pulmonary fi brosis. N Engl J Med. 2014; 370: 2093-101
132. Iyer SN, Gurujeyalakshmi G, Giri SN. Effects of pirfenidone on transforming growth factor-b gene expression at the transcriptional level in bleomycin hamster model of lung fi brosis. J Pharmacol Exper Ther. 1999; 291: 367-73
133. Carter NJ. Pirfenidone: in idiopathic pulmonary fi brosis. Drugs. 2011;71:1721-32
134. Taniguchi H, Ebina M, Kondoh Y, Ogura T, Azuma A, Suga M, et al. Pirfenidone in idiopathic pulmonary fi brosis. Eur Respir J. 2010; 35: 821-9
135. Noble PW, Albera C, Bradford WZ, Costabel U, Glassberg MK, Kardatzke D, et al. Pirfenidone in patients with idiopathic pulmonary fi brosis (CAPACITY): two randomised trials. Lancet. 2011; 377: 1760-9
136. Spagnolo P, Del Giovane C, Luppi F, Cerri S, Balduzzi S, Walters E H, et al. Non-steroid agents for idiopathic pulmonary fi brosis. Cochrane Database Syst Rev. 2010; 9: CD003134
137. King TE Jr, Bradford WZ, Castro-Bernardini S, Fagan EA, Glaspole I, Glassberg MK, et al. A phase 3 trial of pirfenidone in patients with idiopathic pulmonary fibrosis. N Engl J Med. 2014;370:2083-92
138. Hilberg F, Roth GJ, Krssak M, Kautschitsch S, Sommergruber W, Tontsch-Grunt U, et al. BIBF 1120: triple angiokinase inhibitor with sustained receptor blockade and good antitumor Efficacy. Cancer Res. 2008; 68:4774-82
139. Chaudhary NI, Roth GJ, Hilberg F, M ü ller-Quernheim J, Prasse A, Zissel G, et al. Inhibition of PDGF, VEGF and FGF signalling attenuates fi brosis. Eur Respir J. 2007; 29: 976-85
140. Wollin L, Maillet I, Quesniaux V, Holweg A, Ryff el B. Antifi brotic and anti-Inflammatory activity of the tyrosine kinase inhibitor nintedanib in experimental models of lung fi brosis. J Pharmacol Exp Ther. 2014;349:209-20
141. Richeldi L, Costabel U, Selman M, Kim DS, Hansell DM, Nicholson AG, et al. Efficacy of a tyrosine kinase inhibitor in idiopathic pulmonary fi brosis. N Engl J Med. 2011; 365: 1079-87
142. Richeldi L, du Bois RM, Raghu G, Azuma A, Brown KK, Costabel U, et al. Efficacy and safety of nintedanib in idiopathic pulmonary fi brosis. N Engl J Med. 2014; 370: 2071-82
143. Cantin AM, Hubbard RC, Crystal RG. Glutathione defi ciency in the epithelial lining fl uid of the lower respiratory tract in idiopathic pulmonary fi brosis. Am J Respir Crit Care Med. 1989; 139: 370-2
144. Demedts M, Behr J, Buhl R, Costabel U, Dekhuijzen R, Jansen HM, et al. High-dose acetylcysteine in idiopathic pulmonary fi brosis. N Engl J Med. 2005; 353: 2229-42
145. Raghu G, Freudenberger TD, Yang S, Curtis JR, Spada C, Hayes J, et al. High prevalence of abnormal acid gastro-oesophageal refl ux in idiopathic pulmonary fi brosis. Eur Respir J. 2006; 27: 136-42
146. Lee JS, Ryu JH, Elicker BM, Lydell CP, Jones KD, Wolters PJ, et al. Gastroesophageal refl ux therapy is associated with longer survival in patients with idiopathic pulmonary fi brosis. Am J Respir Crit Care Med. 2011; 184: 1390-4
147. Lee JS, Collard HR, Anstrom KJ, Martinez FJ, Noth I, Roberts RS, et al. Anti-acid treatment and disease progression in idiopathic pulmonary fi brosis: an analysis of data from three randomised controlled trials. Lancet Resp Med. 2013; 1: 369-76
148. Th abut G, Mal H, Castier Y, Groussard O, Brugiere O, Marrash-Chahla R, et al. Survival benefi t of lung transplantation for patients with idiopathic pulmonary fi brosis. J Th orac Cardiovasc Surg. 2003;126:469-75
149. Th abut G, Christie JD, Ravaud P, Castier Y, Dauriat G, Jebrak G, et al. Survival aft er bilateral versus single-lung transplantation for idiopathic pulmonary fi brosis. Ann Intern Med. 2009; 151: 767-74
150. George TJ, Arnaoutakis GJ, Shah AS. Lung transplant in idiopathic pulmonary fi brosis. Arch Surg. 2011; 146: 1204-9
151. Christie JD, Edwards LB, Kucheryavaya AY, Benden C, Dobbels F, Kirk R, et al. The Registry of the International Society for Heart and Lung Transplantation: Twenty-eighth adult lung and heart-lung transplant report - 2011. J Heart Lung Transplant. 2011; 30: 1104-22
152. Orens JB, Estenne M, Arcasoy S, Conte JV, Corris P, Egan JJ, et al. International guidelines for the selection of lung transplant candidates: 2006 update - a consensus report from the Pulmonary Scientifi c Council of the International Society for Heart and Lung Transplantation. J Heart Lung Transplant. 2006; 25: 745-55
153. Arizono S, Taniguchi H, Sakamoto K, Kondoh Y, Kimura T, Kataoka K, et al. Endurance time is the most responsive exercise measurement in idiopathic pulmonary fi brosis. Respir Care. 2014; 59: 1108-15
154. Nishiyama O, Kondoh Y, Kimura T, Kato K, Kataoka K, Ogawa T, et al. Effects of pulmonary rehabilitation in patients with idiopathic pulmonary fi brosis. Respirology. 2008; 13: 394-9
155. Nishiyama O, Taniguchi H, Kondoh Y, Kimura T, Ogawa T, Watanabe F, et al. Quadriceps weakness is related to exercise capacity in idiopathic pulmonary fi brosis. Chest. 2005; 127: 2028-33
156. Egan JJ. Follow-up and nonpharmacological management of the idiopathic pulmonary fi brosis patient. Eur Respir Rev. 2011; 20: 114-17
157. Belkin A, Swigris JJ. Health-related quality of life in idiopathic pulmonary fi brosis: where are we now?. Curr Opin Pulm Med. 2013;19:474-9
158. Swigris JJ, Fairclough DL, Morrison M, Make B, Kozora E, Brown KK, et al. Benefi ts of pulmonary rehabilitation in idiopathic pulmonary fi brosis. Respir Care. 2011; 56: 783-9
159. Rammaert B, Leroy S, Cavestri B, Wallaert B, Grosbois JM. Homebased pulmonary rehabilitation in idiopathic pulmonary fi brosis. Rev Mal Respir. 2011; 28: e52-7
160. Allen S, Raut S, Woollard J, Vassallo M. Low dose diamorphine reduces breathlessness without causing a fall in oxygen saturation in elderly patients wiThend-stage idiopathic pulmonary fi brosis. Palliat Med. 2005;19:128-30
161. Ryerson CJ, Berkeley J, Carrieri-Kohlman VL, Pantilat SZ, Landefeld CS, Collard HR. Depression and functional status are strongly associated with dyspnea in interstitial lung disease. Chest. 2011;139:609-16
162. H arrison NK. C ough, sarcoidosis and idiopathic pulmonary fi brosis: raw nerves and bad vibrations. Cough. 2013; 9: 9
163. Kilduff CE, Counter MJ, Thomas GA, Harrison NK, Hope-Gill BD. Effect of acid suppression therapy on gastroesophageal refl ux and cough in idiopathic pulmonary fi brosis: an intervention study. Cough. 2014;10:4
164. Hope-Gill BD, Hilldrup S, Davies C, Newton RP, Harrison NK. A study of the cough refl ex in idiopathic pulmonary fi brosis. Am J Respir Crit Care Med. 2003; 168: 995-1002
165. Horton MR, Santopietro V, Mathew L, Horton KM, Polito AJ, Liu MC, et al. Th alidomide for the treatment of cough in idiopathic pulmonary fi brosis: a randomized trial. Ann Intern Med. 2012; 157: 398-406